• The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    • Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, Jonkers J, Rottenberg S, Chapman JR.
    • Nat Commun. 2018 Dec 17;9(1):5406. doi: 10.1038/s41467-018-07855-x.
    • Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
    • Nicolas E, Bertucci F, Sabatier R, Gonçalves A.
    • Cancers (Basel). 2018 Dec 11;10(12). pii: E506. doi: 10.3390/cancers10120506.
    • Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    • Faraoni I, Graziani G.
    • Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487.
    • BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
    • Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL.
    • Am J Clin Oncol. 2018 Dec;41(12):1252-1256. doi: 10.1097/COC.0000000000000466.
    • A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    • de Souza Timoteo AR, Gonçalves AÉMM, Sales LAP, Albuquerque BM, de Souza JES, de Moura PCP, de Aquino MAA, Agnez-Lima LF, Lajus TBP.
    • Breast Cancer Res Treat. 2018 Dec;172(3):637-646. doi: 10.1007/s10549-018-4938-0. Epub 2018 Aug 29.
    • Talazoparib: First Global Approval.
    • Hoy SM.
    • Drugs. 2018 Dec;78(18):1939-1946. doi: 10.1007/s40265-018-1026-z.
    • Review
    • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    • Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.
    • Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.
    • Li J, Ugalde-Morales E, Wen WX, Decker B, Eriksson M, Torstensson A, Christensen HN, Dunning AM, Allen J, Luccarini C, Pooley KA, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Czene K.
    • Cancer Res. 2018 Nov 1;78(21):6329-6338. doi: 10.1158/0008-5472.CAN-18-1018.
    • Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    • Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.
    • J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.

    Research news:

    Lurbinectedin for BRCA-mutated advanced breast cancer.

    Research news:

    Lurbinectedin Is Active in Patients with BRCA1/2 Mutant Breast Cancer.

    • BRCA mutation in breast cancer patients: Prognostic impact and implications on clinical management.
    • Loi M, Desideri I, Olmetto E, Francolini G, Greto D, Bonomo P, Simontacchi G, Di Brina L, Meattini I, Livi L.
    • Breast J. 2018 Nov;24(6):1019-1023. doi: 10.1111/tbj.13100. Epub 2018 Jul 31.
    • Review
    • Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
    • Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM.
    • Eur J Cancer. 2018 Nov;104:160-168. doi: 10.1016/j.ejca.2018.09.003. Epub 2018 Oct 22.
    • Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy.
    • Song Z, Wang Y, Xiao Q, Yu Z, Zhao L, Wu H, Sun M, Chai Z, Hou P, Geng X, Liu W, Wei M.
    • Oncol Lett. 2018 Nov;16(5):5621-5630. doi: 10.3892/ol.2018.9398. Epub 2018 Sep 5.
    • Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.
    • Skendelas JP, Lee C, Mangino A, Carson WE 3rd.
    • Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.
    • Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
    • Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.
    • Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.
    • FDA Approves PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2018 Oct 16.

    Original research:

    Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

    • RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    • Fan C, Zhang J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2018 Oct 15;143(8):1935-1942. doi: 10.1002/ijc.31579. Epub 2018 Jul 26.
    • Menopausal Status and Outcomes of BRCA Mutation Carriers with Breast Cancer.
    • Carlson K, Chung A, Mirocha J, Donovan C, Estrada S, Siegel E, Giuliano A, Amersi F.
    • Am Surg. 2018 Oct 1;84(10):1584-1588.
    • Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    • Chen X, Li Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Ann Oncol. 2018 Oct 1;29(10):2046-2051. doi: 10.1093/annonc/mdy338.
    • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
    • Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.
    • Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Breast cancer in transgender patients: A systematic review. Part 1: Male to female.
    • Hartley RL, Stone JP, Temple-Oberle C.
    • Eur J Surg Oncol. 2018 Oct;44(10):1455-1462. doi: 10.1016/j.ejso.2018.06.035. Epub 2018 Jul 25.
    • Review
    • Lurbinectedin for BRCA-mutated advanced breast cancer.
    • Gourd E.
    • Lancet Oncol. 2018 Sep 27. pii: S1470-2045(18)30737-X. doi: 10.1016/S1470-2045(18)30737-X. [Epub ahead of print]
    • Research news

    Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

    • Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • Pharm Res. 2018 Sep 25;35(11):218. doi: 10.1007/s11095-018-2502-6.
    • Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    • Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.
    • Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.
    • Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    • Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.
    • Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216.
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
    • Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.
    • Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.
    • Emerging PARP inhibitors for treating breast cancer.
    • Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.
    • Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29.
    • Review
    • Clinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy.
    • Anderson MR, Denson AC, Zaman S, Han HS, Soliman HH.
    • JCO Precis Oncol. 2018 Nov [2018 Aug 31];2:1-5. doi: 10.1200/PO.18.00123.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    • Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.
    • N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.

    Research news:

    Talazoparib for BRCA-mutated advanced breast cancer.

    Press: PARP Inhibitor Talazoparib Benefit in BCRA+ Breast Cancer. (Medscape Oncology)

    Press: FDA Approves PARP Inhibitor Talazoparib in BRCA+ Breast Cancer. (Medscape Oncology)

    • A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status.
    • Su YW, Hung CY, Lam HB, Chang YC, Yang PS.
    • Clin Med Insights Oncol. 2018 Aug 21;12:1179554918794672. doi: 10.1177/1179554918794672. eCollection 2018.
    • The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
    • Guo XX, Wu HL, Shi HY, Su L, Zhang X.
    • Cancer Manag Res. 2018 Aug 10;10:2553-2562. doi: 10.2147/CMAR.S169558. eCollection 2018.
    • Advances in the use of PARP inhibitor therapy for breast cancer.
    • McCann KE, Hurvitz SA.
    • Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.
    • Tamoxifen withdrawal in women with progressive metastatic breast cancer: a case series of six patients.
    • Hagio K, Baba M, Ishida N, Oshino T, Kasahara R, Nara M, Yamashita H.
    • Int Cancer Conf J. 2018 Aug 6;7(4):142-147. doi: 10.1007/s13691-018-0339-9. eCollection 2018 Oct.
    • Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    • Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, Wu J, Shao ZM, Yang WT, Hu XC.
    • Ann Oncol. 2018 Aug 1;29(8):1741-1747. doi: 10.1093/annonc/mdy209.
    • BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
    • Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.
    • J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.

    Commentary:

    A new paradox for pCR in BRCA mutation carriers.

    • Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.
    • Battisti NML, Okonji D, Manickavasagar T, Mohammed K, Allen M, Ring A.
    • Breast. 2018 Aug;40:60-66. doi: 10.1016/j.breast.2018.04.014. Epub 2018 Apr 23.
    • Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy.
    • Zanna I, Silvestri V, Palli D, Magrini A, Rizzolo P, Saieva C, Zelli V, Bendinelli B, Vezzosi V, Valentini V, Bianchi S, Ottini L, Masala G.
    • Breast. 2018 Aug;40:85-91. doi: 10.1016/j.breast.2018.04.017. Epub 2018 Apr 28.
    • Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    • Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP.
    • Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22.
    • BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    • Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, Hack CC, Schrauder MG, Jud SM, Emons J, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Lux MP, Beckmann MW, Fasching PA, Hein A.
    • Breast Cancer Res Treat. 2018 Aug;171(1):85-94. doi: 10.1007/s10549-018-4797-8. Epub 2018 May 3.
    • Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    • Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M.
    • Ann Oncol. 2018 Jul 1;29(7):1497-1508. doi: 10.1093/annonc/mdy127.
    • Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    • Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B.
    • Breast Cancer Res Treat. 2018 Jul;170(1):101-109. doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.
    • BRCA1/2 testing: therapeutic implications for breast cancer management.
    • Tung NM, Garber JE.
    • Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5.
    • Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    • Wang X, Shi Y, Huang D, Guan X.
    • Cancer Treat Rev. 2018 Jul;68:62-68. doi: 10.1016/j.ctrv.2018.05.014. Epub 2018 May 31.
    • Review
    • Responses to carboplatin in BRCA1/2-mutated breast cancer.
    • Burki TK.
    • Lancet Oncol. 2018 Jul;19(7):e337. doi: 10.1016/S1470-2045(18)30407-8. Epub 2018 May 24.
    • Research news
    • A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer.
    • Wheelden M, Cream L, Sivik J, Robson M.
    • Case Rep Oncol Med. 2018 Jun 27;2018:9529821. doi: 10.1155/2018/9529821. eCollection 2018.
    • Association of Germline PALB2 Mutation and Response to Platinum-Based Chemotherapy in Metastatic Breast Cancer: A Case Series.
    • Isaac D, Karapetyan L, Tamkus D.
    • JCO Precis Oncol. 2018 Nov [2018 Jun 26];2:1-5. doi: 10.1200/PO.17.00258.
    • Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
    • Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M.
    • ESMO Open. 2018 Jun 20;3(4):e000361. doi: 10.1136/esmoopen-2018-000361. eCollection 2018.
    • Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.
    • Jin Z, Xu L, Zhang L, Zhao M, Li D, Ye L, Ma Y, Ren S, Yu H, Wang D, Liang C, Chen B.
    • Am J Transl Res. 2018 Jun 15;10(6):1677-1689. eCollection 2018.
    • Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    • Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.
    • Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.
    • Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    • Duma N, Gast KC, Choong GM, Leon-Ferre RA, O'Sullivan CC.
    • Curr Oncol Rep. 2018 Jun 8;20(8):63. doi: 10.1007/s11912-018-0709-7.
    • Review
    • Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort.
    • Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D.
    • JAMA Oncol. 2018 Jun 1;4(6):872-874. doi: 10.1001/jamaoncol.2018.0271.
    • Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
    • Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.
    • Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.
    • Advances in the systemic treatment of triple-negative breast cancer.
    • Lebert JM, Lester R, Powell E, Seal M, McCarthy J.
    • Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150. doi: 10.3747/co.25.3954. Epub 2018 Jun 13.
    • Extent of breast cancer type 1 promoter methylation correlates with clinicopathological features in breast cancers.
    • Sun MY, Chang XZ, Xu GY, Dong Y, Zhou ZJ, Liu T, Wang CQ, Li YS.
    • J Cancer Res Ther. 2018 Jun;14([9] Supplement):S354-S361. doi: 10.4103/0973-1482.235354.
    • Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    • Moore KN, Birrer MJ.
    • Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28.
    • Review
    • Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
    • Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA.
    • Dis Model Mech. 2018 May 18;11(5). pii: dmm032292. doi: 10.1242/dmm.032292.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • Triple negative breast cancer: new therapeutic approaches and BRCA status.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • APMIS. 2018 May;126(5):371-379. doi: 10.1111/apm.12836.
    • Review
    • The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    • Domchek SM.
    • Clin Adv Hematol Oncol. 2018 May;16(5):330-332.

    • Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney.
    • Naher S, Tognela A, Moylan E, Adams DH, Kiely BE.
    • Intern Med J. 2018 May;48(5):567-572. doi: 10.1111/imj.13628.
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder S, Bliss JM.v
    • Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
    • SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Xu L, Che X, Wu Y, Song N, Shi S, Wang S, Li C, Zhang L, Zhang X, Qu X, Teng Y.
    • Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
    • Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.
    • Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J.
    • Hered Cancer Clin Pract. 2018 Apr 27;16:9. doi: 10.1186/s13053-018-0092-2. eCollection 2018.
    • Frequency of pathogenic germline mutations in cancer susceptibility genes in breast cancer patients.
    • Kaur RP, Shafi G, Benipal RPS, Munshi A.
    • Med Oncol. 2018 Apr 26;35(6):81. doi: 10.1007/s12032-018-1143-2.
    • PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    • Turk AA, Wisinski KB.
    • Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16.
    • Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer.
    • Bhattacharyya GS, Walia M, Nandi M, Murli A, Salim S, Rajpurohit S, Shinde S, Aggarwal S, Parikh PM.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):156-158. doi: 10.4103/sajc.sajc_126_18.
    • Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    • Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.
    • Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.
    • Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    • Liljegren A, von Wachenfeldt A, Azavedo E, Eloranta S, Grundström H, Ståhlbom AK, Sundbom A, Sundén P, Svane G, Ulitzsch D, Arver B.
    • Breast Cancer Res Treat. 2018 Apr;168(3):655-666. doi: 10.1007/s10549-017-4639-0. Epub 2018 Jan 9.
    • Predictors of survival for breast cancer patients with a BRCA1 mutation.
    • Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, Szwiec M, Wisniowski R, Birkenfeld B, Kilar E, Sibilski R, Sun P, Lubinski J.
    • Breast Cancer Res Treat. 2018 Apr;168(2):513-521. doi: 10.1007/s10549-017-4605-x. Epub 2017 Dec 15.
    • Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?
    • Jacobson M, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16.
    • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.
    • Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.
    • A Germline Mutation in the BRCA1 3’UTR Variant Predicts Susceptibility to Breast Cancer in a Saudi Arabian Population.
    • Mir R, Javid J, Al Balawi IA, Alkharsah KR, Hadi MA, Rahman MA, Hamoud E, Al Alawi Y, Al Zahrani ABM, Abu-Duhier FM.
    • Asian Pac J Cancer Prev. 2018 Mar 27;19(3):859-866.
    • Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    • Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HS, Yang AS.
    • BMC Cancer. 2018 Mar 22;18(1):315. doi: 10.1186/s12885-018-4229-5.
    • Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.
    • Sengodan SK, Sreelatha KH, Nadhan R, Srinivas P.
    • Crit Rev Oncol Hematol. 2018 Mar;123:74-82. doi: 10.1016/j.critrevonc.2018.01.008. Epub 2018 Feb 2.
    • Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population.
    • Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, Lin J, Sheng Y, Yu Y.
    • Oncol Lett. 2018 Mar;15(3):3068-3074. doi: 10.3892/ol.2017.7717. Epub 2017 Dec 29.
    • p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
    • Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B.
    • Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.
    • A4 Results of cis-platinum treatment of breast cancer patients with brca1 mutation.
    • Narod S, Byrski T, Marczyk E, Wiśniowski R, Szwiec T, Huzarski T, Cybulski C, Dębniak T, Gronwald J, Lubiński J.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A4. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • A11 Similar 10-year survival in breast cancer with patients common BRCA1 mutations in Poland and Lithuania.
    • Elsakov P, Ostapenko V, Luksyte A, Smailyte G.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A11. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.
    • Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111-6. doi: 10.1016/S1470-2045(18)30111-6. [Epub ahead of print]
    • Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    • Yadav P, Masroor M, Nandi K, Kaza RCM, Jain SK, Khurana N, Saxena A.
    • Asian Pac J Cancer Prev. 2018 Feb 26;19(2):443-448.
    • Survival and mutation status in breast cancer patients under age 40.
    • [No author given]
    • FORCE. XRAYS. 2018 Feb 15.

    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    • Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.
    • Banda K, Swisher EM, Wu D, Pritchard CC, Gadi VK.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-6. doi: 10.1200/PO.17.00044.

    Commentary:

    Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.

    • Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.
    • Ganesan S.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-4. doi: 10.1200/PO.18.00001.

    Case report:

    Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    Original research:

    Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

    • Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    • Ibrahim M, Yadav S, Ogunleye F, Zakalik D.
    • BMC Cancer. 2018 Feb 13;18(1):179. doi: 10.1186/s12885-018-4098-y.
    • "Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.
    • Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN.
    • Cureus. 2018 Feb 4;10(2):e2150. doi: 10.7759/cureus.2150.
    • BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    • Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    • Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.
    • Talazoparib Bests Chemo for Breast Cancer.
    • [No authors listed]
    • Cancer Discov. 2018 Feb;8(2):OF3. doi: 10.1158/2159-8290.CD-NB2017-180. Epub 2017 Dec 14.
    • Research news
    • Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    • Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A.
    • Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    • Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.
    • Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    Research news:

    Young women with BRCA mutation can safely postpone radical surgery.

    Press: Survival After Breast Cancer 'Unaffected by BRCA Status' (Medscape)

    Research news: Survival and mutation status in breast cancer patients under age 40. (FORCE: XRAYS)

    • Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
    • Echavarría I, López-Tarruella S, Picornell AC, Garcia-Saenz JA, Jerez-Gilarranz Y, Hoadley KA, Gomez H, Moreno F, Del Monte-Millán M, Marquez-Rodas I, Alvarez EL, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martín M.
    • Clin Cancer Res. 2018 Jan 29. pii: clincanres.1912.2017. doi: 10.1158/1078-0432.CCR-17-1912. [Epub ahead of print]
    • Rationale for Mastectomy after Neoadjuvant Chemotherapy.
    • Gusic LH, Walsh K, Flippo-Morton T, Sarantou T, Boselli D, White RL Jr..
    • Am Surg. 2018 Jan 1;84(1):126-132.
    • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
    • Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.
    • Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

    Commentary:

    Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

    • Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    • Soenderstrup IMH, Laenkholm AV, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, Kruse TA, Larsen MJ, Pedersen IS, Rossing M, Thomassen M, Ejlertsen B.
    • Acta Oncol. 2018 Jan;57(1):95-101. doi: 10.1080/0284186X.2017.1398415. Epub 2017 Nov 22.
    • A Novel Model to Characterize Structure and Function of BRCA1.
    • Lin D, Izadpanah R, Braun SE, Alt E.
    • Cell Biol Int. 2018 Jan;42(1):34-44. doi: 10.1002/cbin.10846. Epub 2017 Oct 25.
    • Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
    • Hjortkjær M, Kanstrup H, Jakobsen A, Steffensen KD.
    • Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27.
    • Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    • Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.
    • Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.
    • A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.
    • Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.
    • NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.
    • Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.
    • Liu C, Chang H, Li XH, Qi YF, Wang JO, Zhang Y, Yang XH.
    • J Cell Biochem. 2017 Dec;118(12):4728-4734. doi: 10.1002/jcb.26140. Epub 2017 Jun 22.
    • Meta-Analysis
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
    • Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.
    • Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.
    • Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.
    • Castells M.
    • Front Immunol. 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. eCollection 2017.
    • VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    • Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A.
    • Int J Cancer. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868. Epub 2017 Jul 20.
    • Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women.
    • Corsini C, Henouda S, Nejima DB, Bertet H, Toledano A, Boussen H, Habib F, Mouhout A, Gaballah A, Ghazaly HE, Bourgier C, Coupier I, Galibert V, Baudry K, Vilquin P, Biquard L, Rey JM, Belkacemi Y, Ihout P, Khayat D, Picot MC, Bensalem A, Pujol P.
    • Breast Cancer Res Treat. 2017 Nov;166(2):631-639. doi: 10.1007/s10549-017-4434-y. Epub 2017 Aug 5.
    • A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy.
    • Shi M, Ma F, Liu J, Xing H, Zhu H, Yu J, Yang M.
    • Breast Cancer Res Treat. 2017 Nov;166(1):109-116. doi: 10.1007/s10549-017-4395-1. Epub 2017 Jul 25.
    • Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
    • Dagan E, Gershoni-Baruch R, Kurolap A, Fried G.
    • Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12594. Epub 2016 Oct 10.
    • Paraneoplastic fasciitis and polyarthritis syndrome as a manifestation of breast cancer recurrence in a BRCA1 gene-positive patient.
    • Kennedy N, Chapman P.
    • Int J Rheum Dis. 2017 Nov;20(11):1876-1878. doi: 10.1111/1756-185X.12773. Epub 2015 Oct 7.
    • Letter
    • A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
    • Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J.
    • Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
    • Clinical and genetic characterization of hereditary breast cancer in a Chinese population.
    • Jian W, Shao K, Qin Q, Wang X, Song S, Wang X.
    • Hered Cancer Clin Pract. 2017 Oct 30;15:19. doi: 10.1186/s13053-017-0079-4. eCollection 2017.
    • The role of BRCA status on prognosis in patients with triple-negative breast cancer.
    • Xie Y, Gou Q, Wang Q, Zhong X, Zheng H.
    • Oncotarget. 2017 Aug 3;8(50):87151-87162. doi: 10.18632/oncotarget.19895. eCollection 2017 Oct 20.
    • Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    • Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.
    • JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.

    Editorial:

    Use of Neoadjuvant Platinum-The Ongoing Conundrum.

    • Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
    • Sharma M, Piplani S, Madan M, Manjari M, Garg S, Kaur K.
    • Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):469-474. doi: 10.4103/IJPM.IJPM_524_16.
    • Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
    • Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ.
    • AJR Am J Roentgenol. 2017 Oct;209(4):920-928. doi: 10.2214/AJR.16.16957. Epub 2017 Aug 10.
    • CHEK2 gene mutations in breast cancer patients with BRCA1/2 positive or negative status.
    • Lobanova O, Rossokha Z, Vereshchako R, Cheshuk V, Popova O, Salomakhina H.
    • Ann Oncol. 2017 Oct;28 Suppl 7:vii7. doi: 10.1093/annonc/mdx508.014.
    • Conference abstract
    • BRCA related breast cancer and sporadic tumors: same prognosis or survivorship bias?
    • Ballatore Z, Bracci R, Bianchi F, Maccaroni E, Belvederesi L, Brugiati C, Murrone A, Pagliaretta S, Pistelli M, Berardi R.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi28. doi: 10.1093/annonc/mdx424.011.
    • PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells).
    • Meena R, Kumar S, Kumar R, Gaharwar US, Rajamani P.
    • Biomed Pharmacother. 2017 Oct;94:944-954. doi: 10.1016/j.biopha.2017.07.151. Epub 2017 Aug 12.
    • Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    • Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, Xiao Y, Best A, Garland L, Xie Y, Hu N, Rodriguez-Herrera M, Wang C, Jones K, Luo W, Hicks B, Tang TS, Moitra K, Rogan PK, Dean M.
    • Breast Cancer Res Treat. 2017 Oct;165(3):687-697. doi: 10.1007/s10549-017-4356-8. Epub 2017 Jun 29.
    • Prognostic impact of germline mutations in inherited cancer syndromes.
    • Corso G, Feroce I, Intra M, Veronesi P, Sacchini V, Bonanni B, Galimberti V.
    • Future Oncol. 2017 Oct;13(24):2125-2127. doi: 10.2217/fon-2017-0296. Epub 2017 Oct 6.
    • Editorial, Review
    • ATM, radiation, and the risk of second primary breast cancer.
    • Bernstein JL; WECARE Study Collaborative Group, Concannon P.
    • Int J Radiat Biol. 2017 Oct;93(10):1121-1127. doi: 10.1080/09553002.2017.1344363. Epub 2017 Jul 27.
    • BRCA2 carriers with male breast cancer show elevated tumour methylation.
    • Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB.
    • BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.
    • BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
    • Mahmoud AM, Macias V, Al-Alem U, Deaton RJ, Kadjaksy-Balla A, Gann PH, Rauscher GH.
    • PLoS One. 2017 Sep 1;12(9):e0184385. doi: 10.1371/journal.pone.0184385. eCollection 2017.
    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    • Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson K.
    • Nat Commun. 2017 Aug 22;8(1):319. doi: 10.1038/s41467-017-00388-9.
    • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    • Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.
    • Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
    • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P.
    • N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.

    Letter:

    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

    Press: Olaparib: New Standard for BRCA-Mutated Breast Cancer? (Medscape)

    • Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    • Somlo G, Frankel P, Arun B, Ma CX, Garcia A, Cigler T, Cream L, Harvey H, Sparano JA, Nanda R, Chew HK, Moynihan T, Goetz MP, Vahdat L, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow K, Chen A, Ruel C, Newman E, Gandara DR, Weitzel JN.
    • Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.
    • Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    • Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ.
    • J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw329.
    • Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
    • Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum JL, Gonçalves A, Campone M, Nieto A, Alfaro V, Cullell-Young M, Lubinski J.
    • Breast. 2017 Aug;34:18-23. doi: 10.1016/j.breast.2017.04.006. Epub 2017 Apr 30.
    • Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    • Harbeck N, Gluz O.
    • Breast. 2017 Aug;34 Suppl 1:S99-S103. doi: 10.1016/j.breast.2017.06.038. Epub 2017 Jun 27.
    • Review
    • Radiation and depression associated with complications of tissue expander reconstruction.
    • Chuba PJ, Stefani WA, Dul C, Szpunar S, Falk J, Wagner R, Edhayan E, Rabbani A, Browne CH, Aref A.
    • Breast Cancer Res Treat. 2017 Aug;164(3):641-647. doi: 10.1007/s10549-017-4277-6. Epub 2017 May 13.
    • Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction.
    • Scannell Bryan M, Argos M, Andrulis IL, Hopper JL, Chang-Claude J, Malone K, John EM, Gammon MD, Daly M, Terry MB, Buys SS, Huo D, Olopade O, Genkinger JM, Jasmine F, Kibriya MG, Chen L, Ahsan H.
    • Breast Cancer Res Treat. 2017 Aug;164(3):707-717. doi: 10.1007/s10549-017-4287-4. Epub 2017 May 13.
    • Olaparib Keeps Hereditary Breast Tumors in Check.
    • [No authors listed]
    • Cancer Discov. 2017 Aug;7(8):OF10. doi: 10.1158/2159-8290.CD-NB2017-085. Epub 2017 Jun 5.
    • Research news
    • Clinical outcomes of female breast cancer according to BRCA mutation status.
    • Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sørensen HT.
    • Cancer Epidemiol. 2017 Aug;49:128-137. doi: 10.1016/j.canep.2017.05.016. Epub 2017 Jun 8.
    • Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
    • Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, Wang L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Clin Cancer Res. 2017 Jul 19. pii: clincanres.3227.2016. doi: 10.1158/1078-0432.CCR-16-3227. [Epub ahead of print]
    • Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
    • Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.
    • Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.
    • Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study.
    • Maishman T, Cutress RI, Hernandez A, Gerty S, Copson ER, Durcan L, Eccles DM.
    • Ann Surg. 2017 Jul;266(1):165-172. doi: 10.1097/SLA.0000000000001930.
    • The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis.
    • Song JL, Chen C, Yuan JP, Sun SR.
    • Fam Cancer. 2017 Jul;16(3):339-349. doi: 10.1007/s10689-017-9969-x.
    • Review
    • Lymph node status as a prognostic factor in BRCA-positive breast cancer.
    • Lee J, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Lee S, Bae Y.
    • J Surg Res. 2017 Jul;215:125-131. doi: 10.1016/j.jss.2017.03.065. Epub 2017 Apr 7.
    • Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
    • Cohen-Sinai T, Cohen Z, Werner H, Berger R.
    • Front Endocrinol (Lausanne). 2017 Jun 29;8:148. doi: 10.3389/fendo.2017.00148. eCollection 2017.
    • Olaparib provides benefit in metastatic breast cancer.
    • Das M
    • Lancet Oncol. 2017 Jun 8. doi: 10.1016/S1470-2045(17)30453-9. [Epub ahead of print]
    • Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
    • Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.
    • Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • Highlights of the San Antonio Breast Cancer Symposium 2016.
    • Benson JR, Jatoi I.
    • Future Oncol. 2017 Jun;13(15):1291-1295. doi: 10.2217/fon-2017-0088. Epub 2017 Jun 26.
    • Current perspectives on CHEK2 mutations in breast cancer.
    • Apostolou P, Papasotiriou I.
    • Breast Cancer (Dove Med Press). 2017 May 12;9:331-335. doi: 10.2147/BCTT.S111394. eCollection 2017.
    • Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    • Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, Peretz T, Kadouri L.
    • Int J Cancer. 2017 May 1;140(9):2145-2149. doi: 10.1002/ijc.30616. Epub 2017 Feb 8.
    • Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation.
    • Galvão VR, Phillips E, Giavina-Bianchi P, Castells MC.
    • J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):816-818. doi: 10.1016/j.jaip.2016.08.012. Epub 2016 Oct 17.
    • BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    • Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y.
    • Genes Chromosomes Cancer. 2017 May;56(5):405-420. doi: 10.1002/gcc.22445. Epub 2017 Mar 7.
    • Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.
    • Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA.
    • Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w.
    • Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    • Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.
    • J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.
    • A Summary of Recent Oncology Research: Changes to the National Cancer Institute's PDQ Information.
    • [No author given]
    • J Natl Cancer Inst. 2017 Apr 13;109(4). pii: djx080. doi: 10.1093/jnci/djx080. Print 2017 Apr.
    • News

    Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.

    • Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    • Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.
    • Elife. 2017 Apr 11;6. pii: e21350. doi: 10.7554/eLife.21350.
    • [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].
    • Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.
    • Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16.
    • [Article in French]
    • A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
    • Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.
    • Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.
    • Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.
    • Parent of Origin and Prognosis in Familial Breast Cancer in Sweden.
    • Wendt C, Lindblom A, Arver B, VON Wachenfeldt A, Margolin S.
    • Anticancer Res. 2017 Mar;37(3):1257-1262.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity.
    • Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Md RI.
    • Genes (Basel). 2017 Feb 2;8(2). pii: E59. doi: 10.3390/genes8020059.
    • Differences in survival for patients with familial and sporadic cancer.
    • Lee M, Reilly M, Lindström LS, Czene K.
    • Int J Cancer. 2017 Feb 1;140(3):581-590. doi: 10.1002/ijc.30476. Epub 2016 Nov 3.
    • The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
    • Pearson EJ, Nair A, Daoud Y, Blum JL.
    • Breast Cancer Res Treat. 2017 Feb;162(1):59-67. doi: 10.1007/s10549-016-4101-8. Epub 2017 Jan 9./cite>
    • Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function.
    • Mgbemena VE, Signer RA, Wijayatunge R, Laxson T, Morrison SJ, Ross TS.
    • Cell Rep. 2017 Jan 24;18(4):947-960. doi: 10.1016/j.celrep.2016.12.075.
    • The fate of BRCA1-related germline mutations in triple-negative breast tumors.
    • Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.
    • Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.
    • Male Breast Cancer.
    • Serdy KM, Leone JP, Dabbs DJ, Bhargava R.
    • Am J Clin Pathol. 2017 Jan 1;147(1):110-119. doi: 10.1093/ajcp/aqw207.
    • Paraneoplastic Dermatomyositis with Cutaneous and Myopathic Disease Responsive to Adrenocorticotropic Hormone Therapy.
    • Wolff M, Mancuso C, Lal K, Dicostanzo D, Gropper C.
    • J Clin Aesthet Dermatol. 2017 Jan;10(1):57-62. Epub 2017 Jan 1.
    • Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.
    • Geurts-Giele WR, van Verschuer VM, van Deurzen CH, van Diest PJ, Pedrosa RM, Collée JM, Koppert LB, Seynaeve C, Dinjens WN.
    • Mod Pathol. 2017 Jan;30(1):15-25. doi: 10.1038/modpathol.2016.145. Epub 2016 Sep 9.
    • Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
    • Liedtke C, Rody A.
    • Rev Recent Clin Trials. 2017;12(2):73-80. doi: 10.2174/1574887112666170307095945.
    • Review
    • Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
    • Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C.
    • PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016.
    • BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, Shida A, Waraya M, Katoh H, Enomoto T, Sengoku N, Kajita S, Hoffman RM, Watanabe M.
    • PLoS One. 2016 Dec 9;11(12):e0165721. doi: 10.1371/journal.pone.0165721. eCollection 2016.
    • Germ line mutations associated with leukemias.
    • Porter CC.
    • Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):302-308.
    • Review
    • Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    • Spugnesi L, Gabriele M, Scarpitta R, Tancredi M, Maresca L, Gambino G, Collavoli A, Aretini P, Bertolini I, Salvadori B, Landucci E, Fontana A, Rossetti E, Roncella M, Naccarato GA, Caligo MA.
    • Genes Chromosomes Cancer. 2016 Dec;55(12):915-924. doi: 10.1002/gcc.22389. Epub 2016 Jul 26.
    • BRCA1 expression in benign and malignant breast lesions.
    • Fernández Á, Reigosa A.
    • Invest Clin. 2016 Dec;57(4):330-51.
    • Tumor characteristics and prognosis in familial breast cancer.
    • Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S.
    • BMC Cancer. 2016 Nov 29;16(1):924.
    • Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Zaaijer LH, van Doorn HC, Mourits MJ, van Beurden M, de Hullu JA, Adank MA, van Lonkhuijzen LR, Vasen HF, Slangen BF, Gaarenstroom KN, Zweemer RP, Vencken PM, Seynaeve C, Kriege M.
    • Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18.
    • BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
    • Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, Huang J, Zhang Z.
    • Oncotarget. 2016 Oct 25;7(43):70113-70127. doi: 10.18632/oncotarget.12158.
    • Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    • Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J.
    • Oncotarget. 2016 Oct 18;7(42):68662-68673. doi: 10.18632/oncotarget.11900.
    • Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    • Muranen TA, Blomqvist C, Dörk T, Jakubowska A, Heikkilä P, Fagerholm R, Greco D, Aittomäki K, Bojesen SE, Shah M, Dunning AM, Rhenius V, Hall P, Czene K, Brand JS, Darabi H, Chang-Claude J, Rudolph A, Nordestgaard BG, Couch FJ, Hart SN, Figueroa J, García-Closas M, Fasching PA, Beckmann MW, Li J, Liu J, Andrulis IL, Winqvist R, Pylkäs K, Mannermaa A, Kataja V, Lindblom A, Margolin S, Lubinski J, Dubrowinskaja N, Bolla MK, Dennis J, Michailidou K, Wang Q, Easton DF, Pharoah PD, Schmidt MK, Nevanlinna H.
    • Breast Cancer Res. 2016 Oct 3;18(1):98. doi: 10.1186/s13058-016-0758-5.
    • BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 2:1 Matched-Pair Analysis.
    • Zavitsanos PJ, Wazer DE, Hepel JT, Leonard KL.
    • Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S59-S60. doi: 10.1016/j.ijrobp.2016.06.153.
    • Conference abstract
    • RING-less BRCA1 Induces PARP Inhibitor and Platinum Resistance.
    • [No authors listed]
    • Cancer Discov. 2016 Oct;6(10):OF6. Epub 2016 Aug 12.
    • Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    • Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D.
    • Medicine (Baltimore). 2016 Oct;95(40):e4975.
    • Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    • Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, Alexiusdottir KK, Stefansdottir H, Munoz Mitev R, Olafsdottir K, Olafsdottir K, Arason A, Stefansdottir V, Olafsdottir EJ, Barkardottir RB, Eyfjord JE, Narod SA, Tryggvadóttir L.
    • Br J Cancer. 2016 Sep 27;115(7):776-783. doi: 10.1038/bjc.2016.249. Epub 2016 Aug 18.
    • Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results.
    • Sung JS, Stamler S, Brooks J, Kaplan J, Huang T, Dershaw DD, Lee CH, Morris EA, Comstock CE.
    • Radiology. 2016 Sep;280(3):716-22. doi: 10.1148/radiol.2016151419. Epub 2016 Apr 20.
    • Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    • Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.
    • Bone Marrow Transplant. 2016 Aug;51(8):1082-6. doi: 10.1038/bmt.2016.82. Epub 2016 Apr 4.
    • Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer.
    • Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BS, Rakha EA, Nolan C, Ellis IO, Green AR.
    • Malays J Pathol. 2016 Aug;38(2):83-92.
    • Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    • Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.
    • BMC Cancer. 2016 Jul 4;16(1):375.
    • BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    • Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I.
    • Eur J Surg Oncol. 2016 Jul;42(7):999-1001. doi: 10.1016/j.ejso.2016.02.246. Epub 2016 Mar 2.
    • Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006.
    • Silverman BG, Lipshitz I, Keinan-Boker L.
    • J Glob Oncol. 2016 Jun 29. doi: 10.1200/JGO.2016.003699. [Epub ahead of print]
    • Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
    • Zhong X, Dong Z, Dong H, Li J, Peng Z, Deng L, Zhu X, Sun Y, Lu X, Shen F, Su X, Zhang L, Gu Y, Zheng H.
    • PLoS One. 2016 Jun 3;11(6):e0156789. doi: 10.1371/journal.pone.0156789. eCollection 2016.
    • Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient.
    • Cai FF, Chen S, Wang MH, Lin XY, Zhang L, Zhang JX, Wang LX, Yang J, Ding JH, Pan X, Shao ZM, Biskup E.
    • Oncotarget. 2016 May 10;7(19):27499-510. doi: 10.18632/oncotarget.8355.
    • Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.
    • Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A.
    • PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016.
    • Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    • Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME.
    • Cancer. 2016 Apr 15;122(8):1178-1184. doi: 10.1002/cncr.29903. Epub 2016 Feb 9.
    • Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
    • Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, Tharmaratnam KU, Hagen AI, Lim Y, Maxwell AJ, Moller P.
    • Hered Cancer Clin Pract. 2016 Apr 14;14:8. doi: 10.1186/s13053-016-0048-3. eCollection 2016.
    • Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer.
    • Jobsen JJ, van der Palen J, Brinkhuis M, Ong F, Struikmans H.
    • Acta Oncol. 2016 Apr;55(4):449-54. doi: 10.3109/0284186X.2015.1074281. Epub 2015 Sep 23.
    • The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
    • Huzarski T, Byrski T, Gronwald J, Cybulski C, Oszurek O, Szwiec M, Gugała K, Stawicka M, Morawiec Z, Mierzwa T, Falco M, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siołek M, Surdyka D, Wiśniowski R, Posmyk M, Domagała P, Sun P, Lubiński J, Narod SA; Polish Breast Cancer Consortium.
    • Breast Cancer Res Treat. 2016 Apr;156(2):371-8. doi: 10.1007/s10549-016-3749-4. Epub 2016 Mar 17.
    • Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    • Thike AA, Tan PH, Ikeda M, Iqbal J.
    • Histopathology. 2016 Apr;68(5):702-12. doi: 10.1111/his.12801. Epub 2015 Nov 2.
    • [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
    • Zhang J, Sun J, Ouyang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT.
    • Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):185-9. doi: 10.3760/cma.j.issn.0253-3766.2016.03.005.
    • Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
    • Dorling L, Barnett GC, Michailidou K, Coles CE, Burnet NG, Yarnold J, Elliott RM, Dunning AM, Pharoah PD, West CM.
    • Clin Cancer Res. 2016 Mar 15;22(6):1413-20. doi: 10.1158/1078-0432.CCR-15-1080. Epub 2015 Oct 28.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    • van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK.
    • J Clin Oncol. 2016 Feb 10;34(5):409-418. doi: 10.1200/JCO.2015.62.3942. Epub 2015 Dec 23.
    • Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis.
    • Holm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, Hall P, Czene K.
    • J Clin Oncol. 2016 Jan 20;34(3):251-8. doi: 10.1200/JCO.2015.63.0624. Epub 2015 Nov 30.
    • miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
    • Zavala V, Pérez-Moreno E, Tapia T, Camus M, Carvallo P.
    • Cancer Biomark. 2016 Jan 18;16(1):99-107. doi: 10.3233/CBM-150545.
    • Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    • Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, Larson RA.
    • Cancer. 2016 Jan 15;122(2):304-311. doi: 10.1002/cncr.29615. Epub 2015 Dec 7.

    Editorial / Commentary

    Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: ATM heterozygotes and radiation

    • A Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin.
    • Hamad L, Khoury T, Vona K, Nestico J, Opyrchal M, Salerno KE.
    • Cureus. 2016 Jan 11;8(1):e454. doi: 10.7759/cureus.454.
    • Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing.
    • Erdahl LM, Boughey JC, Hoskin TL, Degnim AC, Hieken TJ.
    • Ann Surg Oncol. 2016 Jan;23(1):72-7. doi: 10.1245/s10434-015-4660-7. Epub 2015 Jun 12.
    • Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
    • Barac A, Lynce F, Smith KL, Mete M, Shara NM, Asch FM, Nardacci MP, Wray L, Herbolsheimer P, Nunes RA, Swain SM, Warren R, Peshkin BN, Isaacs C.
    • Breast Cancer Res Treat. 2016 Jan;155(2):285-93. doi: 10.1007/s10549-016-3678-2. Epub 2016 Jan 9.
    • Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
    • Steenbruggen TG, Linn SC, Rodenhuis S, Sonke GS.
    • Cureus. 2015 Dec 24;7(12):e433. doi: 10.7759/cureus.433.
    • Early Occurrence of Angiosarcoma in a Woman With a BRCA2 Gene Variation of Unknown Significance Treated With Breast-Conserving Therapy for Bilateral Ductal Carcinoma: A Case Report.
    • Parvez E, Popovic S, Elavathil L, Okawara G, Hodgson N.
    • Clin Breast Cancer. 2015 Dec;15(6):536-8. doi: 10.1016/j.clbc.2015.06.011. Epub 2015 Jun 22.
    • Case report
    • Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    • Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG.
    • Fam Cancer. 2015 Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.
    • Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.
    • Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, Pozzi S, Ferri P, Napolitano M, Federico M, Sacchi S.
    • J Breast Cancer. 2015 Dec;18(4):378-85. doi: 10.4048/jbc.2015.18.4.378. Epub 2015 Dec 23.
    • Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    • Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, Hooning MJ, Jager A.
    • Breast Cancer Res Treat. 2015 Nov;154(1):171-80.

    News:

    A Summary of Recent Oncology Research: Changes to the National Cancer Institute's PDQ Information.

    • Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
    • Kriege M, Jager A, Hollestelle A, Berns EM, Blom J, Meijer-van Gelder ME, Sieuwerts AM, van den Ouweland A, Collée JM, Kroep JR, Martens JW, Hooning MJ, Seynaeve C.
    • J Cancer Res Clin Oncol. 2015 Oct;141(10):1879-87. doi: 10.1007/s00432-015-1981-7. Epub 2015 May 10.
    • Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis.
    • Shao J, Yang J, Wang JN, Qiao L, Fan W, Gao QL, Feng YJ.
    • J Huazhong Univ Sci Technolog Med Sci. 2015 Oct;35(5):629-34. doi: 10.1007/s11596-015-1481-7. Epub 2015 Oct 22.
    • Meta-Analysis, Review
    • Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.
    • Gong L, Dong C, Ouyang W.
    • Clin Cancer Res. 2015 Aug 15;21(16):3806. doi: 10.1158/1078-0432.CCR-15-0418.
    • Comment, Letter

    Meta-Analysis

    Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.

    Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • Breast cancer in pregnancy: an institutional experience.
    • Blanquisett AH, Vicent CH, Gregori JG, Zotano ÁG, Porta VG, Simón AR.
    • Ecancermedicalscience. 2015 Jul 8;9:551. doi: 10.3332/ecancer.2015.551. eCollection 2015.
    • Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers.
    • Özmen V.
    • J Breast Health (2013). 2015 Jul 1;11(3):101-105. doi: 10.5152/tjbh.2015.0001. eCollection 2015.
    • Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
    • Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S.
    • Breast Cancer. 2015 Jul;22(4):327-34. doi: 10.1007/s12282-015-0619-6. Epub 2015 May 30.
    • Meta-Analysis
    • Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.
    • Møller P, Tharmaratnam K, Howell A, Stavrinos P, Sampson S, Wallace A, Maxwell AJ, Hagen AI, Evans DG.
    • Breast Cancer Res Treat. 2015 Jul;152(1):87-94. doi: 10.1007/s10549-015-3448-6. Epub 2015 Jun 3.
    • Family history and outcome of young patients with breast cancer in the UK (POSH study).
    • Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM; POSH Study Steering Group.
    • Br J Surg. 2015 Jul;102(8):924-35. doi: 10.1002/bjs.9816. Epub 2015 May 20.
    • Comment on: Endometrial cancer occurrence five years after breast cancer in BRCA2 mutation patient.
    • Choi MC, Kim MS, Lee GH, Lee JM.
    • Obstet Gynecol Sci. 2015 Jul;58(4):331-2. doi: 10.5468/ogs.2015.58.4.331. Epub 2015 Jul 16.
    • Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
    • Chiang HC, Elledge R, Larson P, Jatoi I, Li R, Hu Y.
    • Breast Cancer (Auckl). 2015 Jun 2;9:25-9. doi: 10.4137/BCBCR.S26774. eCollection 2015.
    • Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    • Menes TS, Terry MB, Goldgar D, Andrulis IL, Knight JA, John EM, Liao Y, Southey M, Miron A, Chung W, Buys SS.
    • Breast Cancer Res Treat. 2015 Jun;151(3):653-60. doi: 10.1007/s10549-015-3419-y. Epub 2015 May 15.
    • Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review.
    • Bernier J, Poortmans P.
    • Breast. 2015 Apr;24(2):100-6. doi: 10.1016/j.breast.2014.12.003. Epub 2014 Dec 31.
    • Review
    • Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
    • Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • BMC Cancer. 2015 Mar 28;15:194. doi: 10.1186/s12885-015-1203-3.
    • Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.
    • Asleh-Aburaya K, Fried G.
    • Springerplus. 2015 Mar 15;4:132. doi: 10.1186/s40064-015-0900-3. eCollection 2015.
    • Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
    • Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Ann Oncol. 2015 Mar;26(3):523-8. doi: 10.1093/annonc/mdu559. Epub 2014 Dec 5.
    • Therogenetics: transferring GWAS technology to the clinic.
    • Cox DG, Heudel PE, Trédan O, Bachelot T.
    • Mutagenesis. 2015 Mar;30(2):213-5. doi: 10.1093/mutage/geu060.
    • Endometrial cancer occurence five years after breast cancer in BRCA2 mutation patient.
    • Oh SE, Kim SH, Kim MS, Kim MK.
    • Obstet Gynecol Sci. 2015 Mar;58(2):175-8. doi: 10.5468/ogs.2015.58.2.175. Epub 2015 Mar 16.
    • Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis.
    • A M Heemskerk-Gerritsen B, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, Kets CM, Keymeulen KB, Koppert LB, Meijers-Heijboer HE, Mooij TM, Tollenaar RA, Vasen HF, Hebon, Hooning MJ, Seynaeve C.
    • Int J Cancer. 2015 Feb 15;136(3):668-677. doi: 10.1002/ijc.29032. Epub 2014 Jul 8.
    • Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy.
    • Davies KR, Cantor SB, Brewster AM.
    • Int J Womens Health. 2015 Feb 4;7:181-7. doi: 10.2147/IJWH.S52380. eCollection 2015.
    • Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature.
    • Drooger JC, Hooning MJ, Seynaeve CM, Baaijens MH, Obdeijn IM, Sleijfer S, Jager A.
    • Cancer Treat Rev. 2015 Feb;41(2):187-196. doi: 10.1016/j.ctrv.2014.12.002. Epub 2014 Dec 8.
    • Review
    • Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
    • van Verschuer VM, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert LB, Verhoog LC, Martens JW, Seynaeve C, van Deurzen CH.
    • Hum Pathol. 2015 Feb;46(2):182-90. doi: 10.1016/j.humpath.2014.10.020. Epub 2014 Nov 15.
    • Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked.
    • Niravath P, Eble T, Contreras A, Li M, Franco LM, Rimawi M.
    • Exp Hematol Oncol. 2015 Jan 6;4(1):1. doi: 10.1186/2162-3619-4-1. eCollection 2015.
    • Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.
    • Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.
    • Clin Cancer Res. 2015 Jan 1;21(1):211-20. doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.

    Comment / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.

    Reply / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.
    • Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J.
    • Breast Cancer Res Treat. 2015 Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21.
    • BRCA2-associated therapy-related acute myeloid leukemia.
    • Rashidi A, Amarillo I, Fisher SI.
    • Med Oncol. 2015 Jan;32(1):371. doi: 10.1007/s12032-014-0371-3. Epub 2014 Nov 27.
    • Letter, Case Report
    • The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.
    • Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers.
    • Maryam Nemati Shafaee, Angelica M. Gutierrez-Barrera, Heather Y. Lin, Banu Arun.
    • J Clin Oncol 33, 2015 (suppl 28S; abstr 3); 2015 Breast Cancer Symposium.
    • Conference Abstract

    Press: Aromatase Inhibitors Reduce Contralateral Breast Cancer Risk in BRCA Mutation Carriers. (Oncotherapy Network)

    • Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.
    • Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E, Espín J, Sánchez M.
    • Breast. 2014 Dec;23(6):721-742. doi: 10.1016/j.breast.2014.10.005. Epub 2014 Nov 7.
    • Meta-Analysis, Review
    • Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study.
    • Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M.
    • Breast Cancer. 2014 Nov;21(6):643-50. doi: 10.1007/s12282-013-0466-2. Epub 2013 Apr 16.
    • Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.
    • Medimegh I, Troudi W, Stambouli N, Khodjet-El-Khil H, Baroudi O, Ayari H, Omrane I, Uhrhammer N, Privat M, Mezlini A, Ayed FB, Romdhane KB, Mader S, Bignon YJ, Elgaaied AB.
    • Med Oncol. 2014 Nov;31(11):255. doi: 10.1007/s12032-014-0255-6. Epub 2014 Oct 2.
    • Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer.
    • Lindström LS, Li J, Lee M, Einbeigi Z, Hartman M, Hall P, Czene K.
    • Ann Oncol. 2014 Oct;25(10):1966-72. doi: 10.1093/annonc/mdu270. Epub 2014 Jul 23.
    • Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    • Noori SF, Gangi A, Nelson ME, Choi M, Mirzadehgan P, Bonk AK, Mirocha J, Amersi F, Giuliano AE.
    • Ann Surg Oncol. 2014 Oct;21(10):3324-9. doi: 10.1245/s10434-014-3904-2. Epub 2014 Jul 22.
    • High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.
    • Nilsson MP, Hartman L, Kristoffersson U, Johannsson OT, Borg A, Henriksson K, Lanke E, Olsson H, Loman N.
    • Breast Cancer Res Treat. 2014 Oct;147(3):571-8. doi: 10.1007/s10549-014-3115-3. Epub 2014 Sep 4.
    • Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21.
    • Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
    • Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, Garber JE.
    • Breast Cancer Res Treat. 2014 Jul;146(1):175-82. doi: 10.1007/s10549-014-2995-6. Epub 2014 May 18.
    • A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
    • Anjum S, Fourkala EO, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M.
    • Genome Med. 2014 Jun 27;6(6):47. doi: 10.1186/gm567. eCollection 2014.

    Press: Prospects for blood test to predict breast cancer risk. (PHG Foundation)

    • Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.
    • Walker MJ, Mirea L, Cooper K, Nabavi M, Glendon G, Andrulis IL, Knight JA, O'Malley FP, Chiarelli AM.
    • Fam Cancer. 2014 Jun;13(2):163-72. doi: 10.1007/s10689-013-9689-9.
    • Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
    • Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.
    • J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

    Comment, Editorial:

    A major step forward for BRCA1/2-related cancer risk management.

    Research news: Oophorectomy in women with BRCA1 or BRCA2 mutations. (Lancet Oncology)

    Press: Early Surgery in BRCA1 Carriers Lowers Ovarian Cancer Risk. (Medscape)

    Press: Young women with BRCA1 mutation 'should remove ovaries earlier'. (Medical News Today)

    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With BRCA Mutations.
    • Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S.
    • J Clin Oncol. 2014 Apr 1;32(10):1093-4. doi: 10.1200/JCO.2013.53.5369. Epub 2014 Feb 18.

    Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.

    • Comparison of breast cancers diagnosed in screening patients in their 40s with and without family history of breast cancer in a community outpatient facility.
    • Destounis SV, Arieno AL, Morgan RC, Cavanaugh D, Seifert PJ, Murphy PF, Somerville PA.
    • AJR Am J Roentgenol. 2014 Apr;202(4):928-32. doi: 10.2214/AJR.13.11194.
    • Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
    • Valachis A, Nearchou AD, Lind P.
    • Breast Cancer Res Treat. 2014 Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25.
    • Meta-Analysis, Review
    • Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study.
    • Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, Chappuis PO, Benhamou S.
    • Breast Cancer Res Treat. 2014 Apr;144(2):379-89. doi: 10.1007/s10549-014-2864-3. Epub 2014 Feb 12.
    • Survival from breast cancer in patients with CHEK2 mutations.
    • Huzarski T, Cybulski C, Wokolorczyk D, Jakubowska A, Byrski T, Gronwald J, Domagała P, Szwiec M, Godlewski D, Kilar E, Marczyk E, Siołek M, Wiśniowski R, Janiszewska H, Surdyka D, Sibilski R, Sun P, Lubiński J, Narod SA.
    • Breast Cancer Res Treat. 2014 Apr;144(2):397-403. doi: 10.1007/s10549-014-2865-2. Epub 2014 Feb 21.
    • A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.
    • Narod SA, Tung N, Lubinski J, Huzarski T, Robson M, Lynch HT, Neuhausen SL, Ghadirian P, Kim-Sing C, Sun P, Foulkes WD; Hereditary Breast Cancer Clinical Study Group.
    • Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.
    • Threshold for genetic testing in women with breast cancer needs to be determined.
    • Basu NN, Barr L, Evans DG, Ross GL.
    • BMJ. 2014 Mar 6;348:g1863. doi: 10.1136/bmj.g1863.
    • Letter

    Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.

    • Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) due to silicone implant incompatibility syndrome in three sisters.
    • Kappel RM, Cohen Tervaert JW, Pruijn GJ.
    • Clin Exp Rheumatol. 2014 Mar-Apr;32(2):256-8. Epub 2014 Apr 9.
    • Case report
    • Bilateral breast cancers.
    • Narod SA.
    • Nat Rev Clin Oncol. 2014 Mar;11(3):157-66. doi: 10.1038/nrclinonc.2014.3. Epub 2014 Feb 4.
    • Review
    • Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
    • Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA.
    • BMJ. 2014 Feb 11;348:g226. doi: 10.1136/bmj.g226.

    Comment, Editorial:

    Contralateral mastectomy for women with hereditary breast cancer.

    Letter, Comment:

    Threshold for genetic testing in women with breast cancer needs to be determined.

    Research News:

    Women with BRCA mutation have better survival rates after double mastectomy.

    Press: Bilateral Mastectomy Ups Survival in BRCA Carriers. (Medscape/Reuters)

    • Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer.
    • Michieletto S, Saibene T, Evangelista L, Barbazza F, Grigoletto R, Rossi G, Ghiotto C, Bozza F.
    • Breast. 2014 Feb;23(1):19-25. doi: 10.1016/j.breast.2013.10.001. Epub 2013 Nov 1.
    • Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.
    • Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N.
    • Breast Cancer Res Treat. 2014 Feb;144(1):133-42. doi: 10.1007/s10549-014-2842-9. Epub 2014 Jan 30.
    • Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations.
    • Park H, Choi DH, Noh JM, Huh SJ, Park W, Nam SJ, Lee JE.
    • Int J Radiat Biol. 2014 Jan;90(1):90-4. doi: 10.3109/09553002.2013.835504. Epub 2013 Sep 19.
    • Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
    • Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E.
    • Oncol Lett. 2014 Jan;7(1):278-284. Epub 2013 Nov 14.
    • BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer.
    • Sambiasi D, Lambo R, Pilato B, Tommasi S, Trojano G, Kardhashi A, Digennaro M, Trojano V, Simone G, Paradiso A.
    • Oncol Rep. 2014 Jan;31(1):365-9. doi: 10.3892/or.2013.2802. Epub 2013 Oct 22.
    • Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
    • Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Liepniece-Karele I, Purkalne G, Teibe U, Trofimovics G, Miklasevics E, Gardovskis J.
    • Fam Cancer. 2013 Dec;12(4):683-9. doi: 10.1007/s10689-013-9646-7.
    • Management of male breast cancer in the United States: a surveillance, epidemiology and end results analysis.
    • Fields EC, DeWitt P, Fisher CM, Rabinovitch R.
    • Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):747-52. doi: 10.1016/j.ijrobp.2013.07.016.
    • Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.
    • Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.
    • J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.

    Letter, Comment:

    Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.

    • Review of risk factors for the development of contralateral breast cancer.
    • Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE.
    • Am J Surg. 2013 Nov;206(5):704-8. doi: 10.1016/j.amjsurg.2013.08.002. Epub 2013 Sep 6.
    • Review
    • The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.
    • Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Breast Cancer Res Treat. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18.
    • The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Oncology. [2013 Nov;]85(5):278-82. doi: 10.1159/000354834. Epub 2013 Nov 6.
    • Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?
    • Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J.
    • Breast. 2013 Oct;22(5):817-23. doi: 10.1016/j.breast.2013.02.008. Epub 2013 Mar 13.
    • Clinical characteristics of breast cancer in patients with an NBS1 mutation.
    • Huzarski T, Cybulski C, Jakubowska A, Byrski T, Gronwald J, Domagała P, Szwiec M, Godlewski D, Kilar E, Marczyk E, Siołek M, Gorski B, Wiśniowski R, Janiszewska H, Surdyka D, Sibilski R, Sun P, Narod SA, Lubiński J; Polish Breast Cancer Consortium.
    • Breast Cancer Res Treat. 2013 Oct;141(3):471-6. doi: 10.1007/s10549-013-2692-x. Epub 2013 Sep 27.
    • Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
    • Huzarski T, Byrski T, Gronwald J, Górski B, Domagala P, Cybulski C, Oszurek O, Szwiec M, Gugala K, Stawicka M, Morawiec Z, Mierzwa T, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siolek M, Surdyka D, Wisniowski R, Posmyk M, Sun P, Lubinski J, Narod SA.
    • J Clin Oncol. 2013 Sep 10;31(26):3191-6. doi: 10.1200/JCO.2012.45.3571. Epub 2013 Aug 12.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    Press: BRCA1 Mutation Not Linked to Worse Cancer Survival (Medscape Oncology)

    • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    • Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson HL, Jakubowska A, Olah E, Gerdes AM, Foretova L, Hopper JL.
    • J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.

    Press: Tamoxifen Cuts Risk for Breast Cancer in BRCA Carriers. (Medscape)

    Press: Tamoxifen for prevention in high-risk breast cancer. (Medical News Today)

    Press: In BRCA, Tamoxifen May Reduce Contralateral Breast Cancer Risk. (Clinical Oncology News)

    • Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.
    • Cardoso-Filho C, Sarian LO, de Oliveira CB, da Silveira Bossi L, Lourenço GJ, Lima CS, Gurgel MS.
    • Cancer Chemother Pharmacol. 2013 Sep;72(3):529-35. doi: 10.1007/s00280-013-2221-y. Epub 2013 Jul 11.
    • Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report.
    • Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative.
    • Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.
    • [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
    • Menkiszak J, Chudecka-Głaz A, Gronwald J, Bedner R, Cymbaluk-Płoska A, Wezowska M, Zielińska D, Rzepka-Górska I.
    • Ginekol Pol. 2013 Sep;84(9):758-64.
    • Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes.
    • Kraeima J, Siesling S, Vliegen IM, Klaase JM, Ijzerman MJ.
    • Br J Cancer. 2013 Aug 20;109(4):866-71. doi: 10.1038/bjc.2013.401. Epub 2013 Jul 16.
    • Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    • Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.
    • Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.
    • Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
    • Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A.
    • Breast Cancer Res Treat. 2013 Jul;140(1):135-42. doi: 10.1007/s10549-013-2583-1. Epub 2013 Jun 20.
    • Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
    • Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T.
    • Breast Cancer Res Treat. 2013 Jul;140(1):207-11. doi: 10.1007/s10549-013-2621-z. Epub 2013 Jul 4.
    • Case report
    • Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
    • Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF; EMBRACE.
    • J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: BRCA risks by age

    Subject: Counseling against RRM in a 60 year old with BRCA2 mutation?

    Press: Cancer Risks for BRCA1 and BRCA2 Mutation Carriers (Medscape)

    • Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
    • Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK.
    • Clin Exp Metastasis. 2013 Jun;30(5):631-42. doi: 10.1007/s10585-013-9567-8. Epub 2013 Feb 1.
    • Breast cancer in women aged 25 years and younger.
    • Dimitrakakis C, Tsigginou A, Zagouri F, Marinopoulos S, Sergentanis TN, Keramopoulos A, Liakou P, Zografos GC, Papadimitriou CA, Dimopoulos MA, Antsaklis A.
    • Obstet Gynecol. 2013 Jun;121(6):1235-40. doi: 10.1097/AOG.0b013e318291ef9a.
    • Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention.
    • Enajat M, Damen TH, Geenen A, Timman R, van der Hulst RR, Mureau MA.
    • Plast Reconstr Surg. 2013 Jun;131(6):1213-22. doi: 10.1097/PRS.0b013e31828bd35e.
    • Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    • Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM.
    • Br J Cancer. 2013 May 28;108(10):2172-7. doi: 10.1038/bjc.2013.144. Epub 2013 Apr 4.
    • Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    • Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L.
    • Breast Cancer Res Treat. 2013 May;139(1):155-61. doi: 10.1007/s10549-013-2540-z. Epub 2013 Apr 25.
    • Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    • Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M.
    • Cancer. 2013 Apr 1;119(7):1344-1348. doi: 10.1002/cncr.27842. Epub 2012 Nov 16.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    • Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives.
    • Evans DG, Howell A, Ingham SL, Buchan I.
    • Breast Cancer Res. 2013 Feb 26;15(1):401. doi: 10.1186/bcr3382.
    • Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
    • Narod SA, Metcalfe K, Lynch HT, Ghadirian P, Robidoux A, Tung N, Gaughan E, Kim-Sing C, Olopade OI, Foulkes WD, Robson M, Offit K, Jakubowska A, Byrski T, Huzarski T, Sun P, Lubinski J.
    • Breast Cancer Res Treat. 2013 Feb;138(1):273-9. doi: 10.1007/s10549-013-2429-x. Epub 2013 Feb 6.
    • [Expression of BRCA1 and WWOX and their clinicopathologic implication in breast carcinomas occurring in young women].
    • Zhang QL, Zhang QH, Cong H, Zhang XL.
    • Zhonghua Bing Li Xue Za Zhi. 2013 Feb;42(2):90-4. doi: 10.3760/cma.j.issn.0529-5807.2013.02.005.
    • [Article in Chinese]
    • Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
    • Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y, Mackey JR, Damaraju S.
    • PLoS One. 2013;8(1):e53850. doi: 10.1371/journal.pone.0053850. Epub 2013 Jan 16.

    Press: Simple Blood Test Reveals DNA Marker That Predicts Breast Cancer Recurrence. (Medical News Today)

    • Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.
    • Li J, Czene K, Brauch H, Schroth W, Saladores P, Li Y, Humphreys K, Hall P.
    • Breast Cancer Res. 2013;15(5):R93.
    • Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
    • Brooks JD, Teraoka SN, Malone KE, Haile RW, Bernstein L, Lynch CF, Mellemkjær L, Duggan DJ, Reiner AS, Concannon P, Schiermeyer K, Lewinger JP; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC.
    • Int J Mol Epidemiol Genet. 2013;4(1):35-48. Epub 2013 Mar 18.
    • Variation in telangiectasia predisposing genes is associated with overall radiation toxicity.
    • Tanteles GA, Murray RJ, Mills J, Barwell J, Chakraborti P, Chan S, Cheung KL, Ennis D, Khurshid N, Lambert K, Machhar R, Meisuria M, Osman A, Peat I, Sahota H, Woodings P, Talbot CJ, Symonds RP.
    • Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1031-6. doi: 10.1016/j.ijrobp.2012.02.018. Epub 2012 Jun 6.
    • BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    • Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.
    • Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.
    • Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    • Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI.
    • Breast Cancer Res Treat. 2012 Oct;135(3):849-55. doi: 10.1007/s10549-012-2183-5. Epub 2012 Aug 19.
    • Predicting breast cancer chemotherapeutic response using a novel tool for microarray data analysis.
    • Cheng J, Greshock J, Painter J, Lin X, Lee K, Zheng S, Menius A.
    • J Integr Bioinform. 2012 Aug 2;9(2):209. doi: 10.2390/biecoll-jib-2012-209.
    • BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
    • Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE.
    • Breast Cancer Res Treat. 2012 Aug;135(1):135-43. doi: 10.1007/s10549-012-2117-2. Epub 2012 Jun 16.
    • Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer.
    • Kwast AB, Liu L, Roukema JA, Voogd AC, Jobsen JJ, Coebergh JW, Soerjomataram I, Siesling S.
    • Br J Cancer. 2012 Jul 24;107(3):549-55. doi: 10.1038/bjc.2012.270. Epub 2012 Jun 19.
    • Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
    • Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wölfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H.
    • J Med Genet. 2012 Jul;49(7):422-8. doi: 10.1136/jmedgenet-2011-100674. Epub 2012 May 31.
    • Pathological complete response in younger and older breast cancer patients.
    • Kołacińska A, Chałubińska J, Błasińska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z.
    • Arch Med Sci. 2012 May 9;8(2):310-5. doi: 10.5114/aoms.2012.28559.
    • Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
    • Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.
    • Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.
    • Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
    • Alli E, Ford JM.
    • DNA Repair (Amst). 2012 May 1;11(5):522-4. doi: 10.1016/j.dnarep.2012.02.003. Epub 2012 Mar 14.
    • Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics.
    • Verkooijen HM, Hartman M, Usel M, Benhamou S, Neyroud-Caspar I, Czene K, Vlastos G, Chappuis PO, Bouchardy C, Rapiti E.
    • Int J Cancer. 2012 May 1;130(9):2103-10. doi: 10.1002/ijc.26206. Epub 2011 Nov 17.
    • Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    • Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I; kConFab authors, McKay MJ, Fox SB.
    • Breast Cancer Res. 2012 Apr 26;14(2):R69.
    • Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment.
    • Finegold DN, Baty CJ, Knickelbein KZ, Perschke S, Noon SE, Campbell D, Karlsson JM, Huang D, Kimak MA, Lawrence EC, Feingold E, Meriney SD, Brufsky AM, Ferrell RE.
    • Clin Cancer Res. 2012 Apr 15;18(8):2382-90. doi: 10.1158/1078-0432.CCR-11-2303. Epub 2012 Feb 20.
    • Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    • Alford SH, Toy K, Merajver SD, Kleer CG.
    • Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.
    • CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    • Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.
    • J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

    See PubMed abstract for multiple related items.

    Press: CYP2D6 Genotype Not Predictive of Tamoxifen Effectiveness. (Medscape)

    Press: Studies show that CYP2D6 genotype does not predict tamoxifen benefit. (EurekAlert!)

    • CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    • Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.
    • J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.

    See PubMed abstract for multiple related items.

    Press: CYP2D6 Genotype Not Predictive of Tamoxifen Effectiveness. (Medscape)

    Press: Studies show that CYP2D6 genotype does not predict tamoxifen benefit. (EurekAlert!)

    • APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.
    • Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.
    • EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.
    • Clinical implications for BRCA gene mutation in breast cancer.
    • Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S.
    • Mol Biol Rep. 2012 Mar;39(3):3097-102. doi: 10.1007/s11033-011-1073-y. Epub 2011 Jun 21.
    • The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C.
    • Cancer. 2012 Feb 15;118(4):899-907. doi: 10.1002/cncr.26351. Epub 2011 Jul 14.

    Press: Some BRCA1 Carriers Less Sensitive to Taxane. (Medscape Reuters)

    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxia telangiectasia.
    • Byrd PJ, Srinivasan V, Last JI, Smith A, Biggs P, Carney EF, Exley A, Abson C, Stewart GS, Izatt L, Taylor AM.
    • Br J Cancer. 2012 Jan 17;106(2):262-8. doi: 10.1038/bjc.2011.534. Epub 2011 Dec 6.
    • Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation.
    • Yu KD, Huang AJ, Fan L, Li WF, Shao ZM.
    • Cancer Res. 2012 Jan 15;72(2):408-19. doi: 10.1158/0008-5472.CAN-11-2998. Epub 2011 Dec 6.
    • Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    • Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA.
    • J Clin Oncol. 2012 Jan 1;30(1):19-26. doi: 10.1200/JCO.2010.33.0068. Epub 2011 Dec 5.

    Comment/Editorial:

    Should all women with breast cancer be tested for BRCA mutations at the time of diagnosis?

    Press: Does a BRCA Mutation Influence Breast Cancer Outcomes? (Medscape Genomic Medicine)

    • Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations.
    • Singer CF, Zabkova P, Rappaport C, Muhr D, Pfeiler G, Gschwantler-Kaulich D, Fink-Retter A, Staudigl C, Walter I, Hudelist G, Spiess AC, Kubista E.
    • Curr Cancer Drug Targets. 2012 Jan;12(1):44-50.